Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
수요일, 9월 02

Gilead Sciences Inc

GILDNASDAQ
Trade with Public
Trade with Public
$149.92
3.582.45%
가까이에: Sep 1, 5:00 PM EST
$150.00
0.080.05%
시간외: 6:24 PM EST
배당금: 배당락일은 13일 후입니다
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Gilead Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gilead Sciences (GILD).

Price Target Range — 8 Quarters

Analyst Consensus — 23 Analysts

19Buy
4Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$135Upside to Avg. PT-9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026RBC CapitalBrian AbrahamsPT RaiseSector Perform$120→$123
Aug 5, 2026Cantor FitzgeraldCarter GouldMaintainedOverweight$155
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
CNBC Halftime Report Final Trades: Airbnb, Gilead Sciences, KLA, Snowflake

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $120 to $123.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $145

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $155 to $145.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved